NASDAQ:ONXX - Onyx Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Onyx Pharmaceuticals (NASDAQ:ONXX)

Onyx Pharmaceuticals logoOnyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).

Receive ONXX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Onyx Pharmaceuticals (NASDAQ:ONXX) Frequently Asked Questions

What is Onyx Pharmaceuticals' stock symbol?

Onyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ONXX."

Has Onyx Pharmaceuticals been receiving favorable news coverage?

News articles about ONXX stock have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Onyx Pharmaceuticals earned a news sentiment score of 0.13 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.77 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Onyx Pharmaceuticals?

Shares of ONXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Onyx Pharmaceuticals?

Onyx Pharmaceuticals' mailing address is 249 E Grand Ave, SOUTH SAN FRANCISCO, CA 94080-4804, United States. The biopharmaceutical company can be reached via phone at +1-650-2660000.

MarketBeat Community Rating for Onyx Pharmaceuticals (ONXX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  279 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  483
MarketBeat's community ratings are surveys of what our community members think about Onyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ONXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONXX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Onyx Pharmaceuticals (NASDAQ:ONXX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/27/2016 forward)


Onyx Pharmaceuticals (NASDAQ:ONXX) Earnings History and Estimates Chart

Earnings by Quarter for Onyx Pharmaceuticals (NASDAQ:ONXX)

Onyx Pharmaceuticals (NASDAQ ONXX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2013Q2 2013($0.42)($0.40)$151.73 million$153.00 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.47)($0.19)$134.36 million$145.50 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.76)($0.36)$113.17 million$127.90 millionViewN/AView Earnings Details
11/1/2012Q312($0.95)($0.79)$80.02 million$89.51 millionViewN/AView Earnings Details
8/1/2012($0.69)($0.68)ViewN/AView Earnings Details
5/2/2012($0.60)($0.68)ViewN/AView Earnings Details
2/22/2012$1.61$1.50ViewN/AView Earnings Details
11/2/2011($0.27)($0.31)ViewN/AView Earnings Details
8/3/2011($0.17)($0.43)ViewN/AView Earnings Details
5/4/2011($0.13)($0.23)ViewN/AView Earnings Details
2/23/2011($0.02)($0.28)ViewN/AView Earnings Details
11/3/2010Q3 2010($0.04)$0.66ViewN/AView Earnings Details
8/4/2010Q2 2010($0.03)($0.05)ViewN/AView Earnings Details
5/4/2010Q1 2010$0.01($0.10)ViewN/AView Earnings Details
2/23/2010Q4 2009$0.20$0.04ViewN/AView Earnings Details
11/3/2009Q3 2009$0.22$0.29ViewN/AView Earnings Details
8/4/2009Q2 2009$0.14$0.16ViewN/AView Earnings Details
5/6/2009Q1 2009$0.18$0.07ViewN/AView Earnings Details
2/23/2009Q4 2008($0.53)($0.53)ViewN/AView Earnings Details
11/6/2008Q3 2008$0.01$0.21ViewN/AView Earnings Details
8/5/2008Q2 2008$0.10$0.08ViewN/AView Earnings Details
5/6/2008Q1 2008($0.07)$0.27ViewN/AView Earnings Details
2/19/2008Q4 2007($0.05)($0.21)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Onyx Pharmaceuticals (NASDAQ:ONXX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Onyx Pharmaceuticals (NASDAQ ONXX) Insider Trading and Institutional Ownership History

Insider Trading History for Onyx Pharmaceuticals (NASDAQ:ONXX)

Onyx Pharmaceuticals (NASDAQ ONXX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2013Helen TorleyEVPSell9,311$126.89$1,181,472.7946,585View SEC Filing  
8/8/2013Matthew FustCFOSell2,492$128.21$319,499.3240,303View SEC Filing  
8/7/2013Suzanne ShemaEVPSell4,052$131.86$534,296.7234,618View SEC Filing  
8/6/2013Kaye Foster-CheekSVPSell8,878$132.81$1,179,087.1827,066View SEC Filing  
7/30/2013Corinne H NevinnyDirectorSell1,500$131.26$196,890.00View SEC Filing  
7/26/2013Lopez Antonio J GrilloDirectorSell2,000$130.50$261,000.00View SEC Filing  
7/26/2013Matthew K FustCFOSell6,043$130.50$788,611.50View SEC Filing  
7/8/2013Suzanne M ShemaEVPSell4,052$135.76$550,099.52View SEC Filing  
7/2/2013Matthew K FustCFOSell1,551$132.80$205,972.80View SEC Filing  
7/1/2013Juergen LasowskiEVPSell25,375$132.63$3,365,486.25View SEC Filing  
7/1/2013Julianna R WoodVPSell2,304$132.63$305,579.52View SEC Filing  
7/1/2013Paul GoddardDirectorSell6,000$132.21$793,260.00View SEC Filing  
6/19/2013Corinne H NevinnyDirectorSell1,000$88.25$88,250.00View SEC Filing  
6/10/2013Julianna R WoodVPSell2,306$92.30$212,843.80View SEC Filing  
6/7/2013Suzanne M ShemaEVPSell4,052$91.23$369,663.96View SEC Filing  
6/5/2013N Anthony ColesCEOSell6,562$90.00$590,580.00View SEC Filing  
5/14/2013Juergen LasowskiEVPSell4,182$96.60$403,981.20View SEC Filing  
5/13/2013Helen TorleyEVPSell8,250$98.13$809,572.50View SEC Filing  
5/13/2013Matthew K FustCFOSell10,269$98.22$1,008,621.18View SEC Filing  
4/11/2013Lopez Antonio J GrilloDirectorSell43,164$96.73$4,175,253.72View SEC Filing  
4/10/2013Julianna R WoodVPSell9,948$95.00$945,060.00View SEC Filing  
4/10/2013Paul GoddardDirectorSell2,000$95.00$190,000.00View SEC Filing  
3/11/2013Julianna R WoodVPSell3,331$85.65$285,300.15View SEC Filing  
3/11/2013Magnus LundbergDirectorSell5,000$88.00$440,000.00View SEC Filing  
10/5/2012Juergen LasowskiEVPSell5,902$90.00$531,180.00View SEC Filing  
10/4/2012Helen TorleyEVPSell2,314$86.51$200,184.14View SEC Filing  
10/2/2012Kaye I Foster-CheekSVPSell2,015$85.08$171,436.20View SEC Filing  
(Data available from 1/1/2013 forward)


Onyx Pharmaceuticals (NASDAQ ONXX) News Headlines

Google unit stakes biotech claim with lease of entire Onyx campusGoogle unit stakes biotech claim with lease of entire Onyx campus - February 18 at 9:31 AM
Former Teva CEOs new gig at Ovid TherapeuticsFormer Teva CEO's new gig at Ovid Therapeutics - April 16 at 6:10 AM

SEC Filings

Onyx Pharmaceuticals (NASDAQ:ONXX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Onyx Pharmaceuticals (NASDAQ:ONXX) Income Statement, Balance Sheet and Cash Flow Statement


Onyx Pharmaceuticals (NASDAQ ONXX) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.